Join us for Harnessing the Potential of Antibody Drug Conjugates (ADCs) in Oncology, on October 25 at Johnson & Johnson Innovation – JLABS @ Washington, DC. We’ll host industry thought leaders  as they dig deeper on how ADCs have become a promising cancer treatment and key component in the next generation of oncology therapeutics.

Dubbed ‘the next pillar of cancer therapeutics’, ADC technology delivers highly potent treatment agents to specific tumor cells connected to malignancy. From 2019 – 2022, 8 ADCs received FDA approval and dozens more investigational treatments flooded the industry pipeline. Our program will explore the resurgence around their potential in oncology, showcasing innovation in ADC development, exploring the current science and regulatory landscape for oncology, and highlighting investors’ perspectives as breakthrough research that requires support pours in.

After the programming concludes, there will be an opportunity to participate in partnering meetings to connect one-on-one with industry leaders in this space.  All individuals (startups, oncology companies, academics and researchers, industry partners) interested in being considered for an opportunity for one-on-one partnering will need to apply by Friday, October 6th. Selected companies will be notified of their acceptance on Wednesday, October 18th.